AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01320475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)
Study NCT01320475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Epidural infusion of levobupivacaine (1,25 mg/ml) and saline (1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of ketamine (2 µg/kg/minute) Up to the third postoperative day (6 PM)
Study NCT01836588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional cervix biopsy
Description: Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions.
Study NCT02102035 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Direct and reversed dorsal digital island flap
Description: The direct dorsal digital island flap is used to cover the defects of adjacent fingers. The reversed dorsal digital island flap is used to cover the defects of the same fingers.
Study NCT04511481 — intervention group
Intervention type: OTHER
Intervention: Radiomic Algorithm
Description: Different radiomic and machine learning strategies for radiomic features extraction, sorting features and model constriction
Study NCT01192997 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menveo
Description: Single dose Menveo (a MenACWY vaccine conjugated to CRM-197).
Study NCT01192997 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-TT
Description: Single dose MenACWY-TT (MenACWY vaccine conjugated to Tetanus Toxoid, TT)
Study NCT04051398 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: transcutaneous nerve electrostimulation (TENS) of acupuncture points
Description: TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes.
Study NCT04051398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous nerve electrostimulation (TENS) of acupuncture points
Description: TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes.
Study NCT03110471 — intervention group
Intervention type: BEHAVIORAL
Intervention: West Wales Adverse Drug Reaction (WWADR) Profile
Description: Nurse-led medicines' monitoring in care homes: a process evaluation of the impact and sustainability of the West Wales Adverse Drug Reaction (WWADR) Profile and pharmacist involvement
Study NCT03110471 — intervention group
Intervention type: BEHAVIORAL
Intervention: usual care
Description: usual care
Study NCT01428258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GMP Diet/GMP Medical Foods
Description: The intervention consists of a low-phenylalanine (Phe) diet in combination with medical foods made with the peptide GMP supplemented with limiting indispensable amino acids, as provided by Cambrooke Therapeutics, LLC. The diet is formulated to replace the protein equivalents provided by AA medical foods with GMP medical foods, keeping other dietary components constant. The GMP dietary treatment period consists of all subjects following the GMP diet for 3-wks at home. The GMP diet intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
Study NCT01428258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AA Diet/AA Medical Foods
Description: The intervention consists of a low-Phe diet in combination with commercial AA medical foods as consumed in each subject's usual diet. A total of 15 different commercial AA medical foods were consumed by subjects in the study. The diet is formulated to provide each subject with their typical daily intake of protein equivalents from AA medical foods. The AA dietary treatment period consists of all subjects following the AA diet for 3-wks at home. The AA Diet comparator intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
Study NCT04101071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modular ketogenic feed
Description: Dietician prescribed, and consisting of Betaquik® (from Vitaflo, Nutritional company) to provide medium chain triglycerides), Renapro Shot® (protein), Maxijul® (carbohydrate) and multivitamins according to nutritional need (energy and protein requirements) based on clinical status of the participant. Ketogenic feed to be given continuously via nasogastric tube for 10 days
Study NCT04101071 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard feed
Description: Standard Enteral feed. Dietician prescribed based on clinical status of the participant, as per individual Trust protocols. Standard feed to be given continuously via nasogastric tube for 10 days
Study NCT01174407 — intervention group
Intervention type: OTHER
Intervention: cd 35, cd21, cd55
Description: Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient
Study NCT04739826 — intervention group
Intervention type: DRUG
Intervention: Flumatinib Mesylate
Description: Flumatinib mesylate tablets 600mg qd
Study NCT04739826 — intervention group
Intervention type: DRUG
Intervention: Nilotinib Pill
Description: Nilotinib Capsules 300mg bid
Study NCT01913561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Master Caution Garment
Description: Master Caution Garment is embedded with 10/13 textile dry electrodes that enable 12/15-lead ECG.~The electrodes are dry, textile ECG electrodes.
Study NCT01913561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG gel electrodes
Description: Standard gel electrodes that are been in use in hospital for ECG monitoring.
Study NCT04189367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine
Description: One bag of  Qingre Liangkou Ningxin Fang at a time, three times a day for 12 weeks.
Study NCT04189367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Western medicine
Description: Western medicine includes:~1. clonazepam 0.5mg every day before sleep or twice a day for 12 weeks~2. Nutritional supplement: vitamin B12, folic acid, iron, zinc, vitamin B complex depending on the hematic deficiency, for 12 weeks
Study NCT04189367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Western medicine
Description: Western medicine includes:~1. clonazepam 0.5mg every day before sleep or twice a day for 12 weeks~2. Nutritional supplement: vitamin B12, folic acid, iron, zinc, vitamin B complex depending on the hematic deficiency, for 12 weeks
Study NCT02463916 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: 8 week structured exercise programme
Study NCT02542046 — intervention group
Intervention type: DRUG
Intervention: Barium
Description: Administration of barium oral contrast agent prior to CT scan
Study NCT02542046 — intervention group
Intervention type: DRUG
Intervention: Diatrizoate
Description: Administration of diatrizoate oral contrast agent prior to CT scan
Study NCT02542046 — intervention group
Intervention type: DRUG
Intervention: Iohexol
Description: Administration of iohexol oral contrast agent prior to CT scan
Study NCT04214223 — intervention group
Intervention type: OTHER
Intervention: Pre-Anesthesic Consultation
Description: Classical Pre-Anesthesic Consultation with an anesthesist of the maternity hospital of Nancy (France)
Study NCT04214223 — intervention group
Intervention type: OTHER
Intervention: Pre-Anesthesic Numerical Evaluation
Description: Home-based Pre-Anesthesic Numerical Evaluation with the aid of a questionnaire, achieved with a computer, digital tablet or smartphone, on a secured platform.
Study NCT01479101 — intervention group
Intervention type: OTHER
Intervention: MammaPrint 70-gene expression profile
Study NCT01479101 — intervention group
Intervention type: OTHER
Intervention: BluePrint 80 gene expression profile
Study NCT02343146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Type One Training (TOT)
Description: The intervention is comprised of a number of modes of delivery including in person, use of parent peer consultant, telephone intervention, and text messaging. The intervention is based on Social Cognitive Theory and previous work of the investigators.The focus of the intervention is on working with parents to improve child eating and physical activity behaviors as a means of improving glycemic control in very young children with type 1 diabetes.
Study NCT04233008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter length
Description: see arm description
Study NCT00416624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Study NCT00416624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin alfa
Study NCT00416624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fatigue assessment and management
Study NCT00416624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT02849379 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance
Study NCT02849379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Percutaneous ablation under CT or ultrasound guidance
Study NCT02849379 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
Study NCT04674891 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: baseline physical therapy treatment
Description: Group A was control group and the patients received Conventional treatment protocol for 4 weeks which included 3 sessions per week. Patients received hot pack for 15 min and TENS (Transcutaneous Electric Nerve Stimulation) for 10 min. After that Cervical isometric exercises will be performed in sitting (10sec hold,10 to 15 reps)
Study NCT04674891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Stabilization exercises
Description: Group B was experimental group and received baseline physiotherapy treatment in addition to Cervical Stabilization exercises. Pillow was placed beneath cervical spine in supine position and guided patients to nod head as though they said 'yes' and asked them to hold for 10 seconds. 10 repetitions were done before progressing to the next target level.~4 weeks (3 sessions per week)~* Hot pack: 10 min~* TENS: 10 min~* Cervical isometric exercises in sitting (10sec hold,10 to 15 reps)~* Cervical Stabilization exercises (10 sec hold, 10 reps)~On eligible participants baseline assessment was taken on day 1, post intervention assessment was taken at the end of 4th week.
Study NCT02372877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amicus Red Cell Exchange in SCD patients
Description: Each patient will be treated with one RBCx procedure using the AMICUS RBCx System
Study NCT01640002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propantheline Bromide
Description: 15MG OF PROPANTHELINE BROMIDE, THREE TIMES DAILY FOR 02 MONTHS.
Study NCT01640002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PLACEBO CAPSULE, 03 TIMES DAILY FOR 02 MONTHS
Study NCT04463472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0301-COVID19
Description: 1.0 mg of AG0301-COVID19 twice at 2-week intervals
Study NCT04463472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0301-COVID19
Description: 2.0 mg of AG0301-COVID19 twice at 2-week intervals
Study NCT01905098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sauna Detoxification Protocol
Description: All study participants will actively undergo sauna intervention sessions.~The sauna will be pre-warmed to 160 degrees Fahrenheit and humidity set to 25% +/- 5%. Participants will have a scheduled 10-min break every 30 minutes of sauna, during which time vital signs, symptoms, and fluid intake will be assessed and recorded.~On a weekly basis, lab assessments will be performed to compare participants' baseline lab values with those during the sauna intervention, and to monitor for safety. In addition, weekly serum samples will be taken for PCB assessment.
Study NCT01905098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sauna Detoxification Protocol
Description: All study participants will actively undergo sauna intervention sessions.~The sauna will be pre-warmed to 160 degrees Fahrenheit and humidity set to 25% +/- 5%. Participants will have a scheduled 10-min break every 30 minutes of sauna, during which time vital signs, symptoms, and fluid intake will be assessed and recorded.~On a weekly basis, lab assessments will be performed to compare participants' baseline lab values with those during the sauna intervention, and to monitor for safety. In addition, weekly serum samples will be taken for PCB assessment.
Study NCT01905098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation Sessions
Description: All enrolled participants will undergo observation protocol consisting of one (1) hour visit weekly consistent with Sauna Visits lab assessment time points, to be completed in 3 weeks (4 total sessions within 21 days). At each Observation Visit a blood draw for CBC/D, CMP, and PCBs analysis will be performed, as well as query for symptoms and MOSES questionnaire will be assessed.
Study NCT01905098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation Sessions
Description: All enrolled participants will undergo observation protocol consisting of one (1) hour visit weekly consistent with Sauna Visits lab assessment time points, to be completed in 3 weeks (4 total sessions within 21 days). At each Observation Visit a blood draw for CBC/D, CMP, and PCBs analysis will be performed, as well as query for symptoms and MOSES questionnaire will be assessed.
Study NCT02590796 — intervention group
Intervention type: OTHER
Intervention: No intervention given to participants
Description: This is an observational study. Participants will receive no intervention.
Study NCT02489435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VM-1500
Description: VM-1500
Study NCT02489435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02971423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX2514
Study NCT02971423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo infusion
Study NCT02996331 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2 hour repositioning
Description: Current PrU prevention protocols recommend repositioning moderate, high, and severe risk residents a minimum of every 2 hours. We propose to include low risk residents because studies suggest they too develop PrUs. New pressure redistribution mattresses may make 2 hour repositioning unnecessary, but optimal time between repositioning remains unclear. Aim is to determine differences in incidence of new PrUs in NH residents (low, moderate, high risk level) using VE surfaces and repositioned at 2, 3, and 4 hour frequencies.
Study NCT02996331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 hour repositioning
Description: It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 3 hour repositioning interval.
Study NCT02971423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam
Study NCT02971423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/Cilastatin
Study NCT00768989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: Capsules, Oral, 300 mg, twice daily, 96 weeks
Study NCT00768989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Tablet, Oral, 400 mg, twice daily, 96 weeks
Study NCT00768989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: Capsules, Oral, 300 mg, once daily, 96 weeks
Study NCT00768989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: Capsules, Oral, 100 mg, once daily, 96 weeks
Study NCT00768989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/Emtricitabine
Description: Tablet, Oral, 300-mg Tenofovir/200-mg Emtricitabine, once daily, 96 weeks
Study NCT00285896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon-like-peptide-1 (7-36) amide
Description: Continuous, subcutaneous GLP-1 at a dose of 4.8 pmol/kg/min for 51 hours
Study NCT00285896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: continuous subcutaneous placebo infusion at a dose of 4.8 pmol/kg/min for 51 hours
Study NCT00888693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-288
Description: See Arm Description for details.
Study NCT00888693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Description for details.
Study NCT02996331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4 hour repositioning
Description: It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 4 hour repositioning interval.
Study NCT02414932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland
Study NCT02414932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam 0.045 mg/kg; Roche Products Ireland Ltd
Study NCT02904798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypodium Leucotomos
Description: - PL 240mg to be taken by the patient for 28 days prior to irradiation with visible light
Study NCT05638932 — intervention group
Intervention type: DRUG
Intervention: Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)
Description: Real world use of either IL6Ri (TCZ or SAR) or JAKi (BAR or TOF)
Study NCT02745197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement
Description: Participants will take 2 capsules, containing the nutritional supplement, 3 times per day.
Study NCT02745197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take 2 capsules, containing a placebo, 3 times per day.
Study NCT02834481 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ANI/NIPE
Description: ANI/NIPE monitors is a continuous noninvasive measurement of the parasympathetic tone, as a component of the autonomous nervous system. It uses the tiny variations of heart rate induced by each respiratory cycle (natural or induced) to quantify parasympathetic tone (respiratory sinus arrhythmia).
Study NCT02050113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Made Fenestrated or Branched Stent Graft
Description: The surgeon will place a custom made graft, t-Branch device or modify commercially available stent grafts to match the anatomy of the patient being treated. Small fenestrations (holes) will be made in the stent graft so that additional stents can be inserted through the fenestration and into the blood vessels that lead to the kidneys, intestines or liver. These stents allow blood to flow freely to these organs. If the aneurysm is in the aortic arch stents may be placed in the carotid and subclavian arteries. This surgery is done through small incisions in the groin and sometimes in the upper arm.
Study NCT03205124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is given at a fixed continuous frequency of 20Hz. The stimulus intensity is the maximum tolerable limit. The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery.
Study NCT03205124 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is begun until the patient senses the stimulation, then the stimulation is discontinued.The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery.